Arvinas Inc (ARVN)

Overview News Price History Option Chain Discussions Forecast

Arvinas Inc stock is currently priced at $34.72, with a 24-hour trading volume of 917.47K. It has seen a +1.25% increased in the last 24 hours and a -18.42% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $33.79 pivot point. If it approaches the $34.96 resistance level, significant changes may occur.

Arvinas Inc Stock (ARVN) Financials Data

Arvinas Inc (ARVN) Revenue 2024

ARVN reported a revenue (TTM) of $78.50 million for the quarter ending December 31, 2023, a -40.21% decline year-over-year.

Arvinas Inc (ARVN) Net Income 2024

ARVN net income (TTM) was -$367.30 million for the quarter ending December 31, 2023, a -30.02% decrease year-over-year.

Arvinas Inc (ARVN) Cash Flow 2024

ARVN recorded a free cash flow (TTM) of -$350.70 million for the quarter ending December 31, 2023, a -25.12% decrease year-over-year.

Arvinas Inc (ARVN) Earnings per Share 2024

ARVN earnings per share (TTM) was -$6.50 for the quarter ending December 31, 2023, a -22.18% decline year-over-year.

Arvinas Inc Stock (ARVN) Latest News

Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate

Zacks Investment Research

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

GlobeNewswire Inc.

Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Benzinga

Arvinas Holding Company, LLC, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas Holding Company, LLC was founded in 2015 and is based in New Haven, Connecticut.

Downgrade	Citigroup: Buy → Neutral	Feb-14-24
Initiated	Goldman: Buy	Feb-01-24
Upgrade	Wells Fargo: Equal Weight → Overweight	Dec-19-23
Upgrade	Jefferies: Hold → Buy	Dec-06-23
Upgrade	Guggenheim: Neutral → Buy	Nov-20-23
Upgrade	Wedbush: Neutral → Outperform	Oct-23-23
Resumed	Oppenheimer: Outperform	Jun-26-23
Downgrade	Guggenheim: Buy → Neutral	Jan-12-23
Downgrade	Wells Fargo: Overweight → Equal Weight	Jan-03-23
Initiated	Barclays: Overweight	Sep-09-22
Initiated	Jefferies: Hold	Jun-21-22
Downgrade	Wedbush: Outperform → Neutral	May-09-22
Initiated	Credit Suisse: Outperform	Apr-28-22
Initiated	Morgan Stanley: Equal-Weight	Apr-06-22
Resumed	BMO Capital Markets: Outperform	Feb-11-22
Initiated	Wells Fargo: Overweight	Feb-10-22
Initiated	Goldman: Buy	Jan-19-22
Initiated	Cowen: Outperform	Dec-07-21
Initiated	SVB Leerink: Outperform	Oct-14-21
Initiated	Stifel: Buy	Sep-30-21
Initiated	BofA Securities: Buy	Sep-09-21
Initiated	UBS: Buy	May-21-21
Initiated	Truist: Buy	Apr-21-21
Initiated	BMO Capital Markets: Outperform	Mar-31-21
Upgrade	Oppenheimer: Perform → Outperform	Dec-14-20
Upgrade	Citigroup: Neutral → Buy	Jun-01-20
Initiated	Oppenheimer: Perform	May-12-20
Initiated	H.C. Wainwright: Buy	Dec-19-19
Initiated	Guggenheim: Buy	Nov-25-19
Upgrade	Goldman: Neutral → Buy	Oct-24-19
Initiated	Wedbush: Outperform	Sep-25-19
Initiated	BMO Capital Markets: Outperform	Sep-12-19
Initiated	Cantor Fitzgerald: Overweight	Aug-06-19
Downgrade	Citigroup: Buy → Neutral	Jun-05-19
Initiated	Evercore ISI: Outperform	Apr-12-19
Initiated	Citigroup: Buy	Oct-22-18
Initiated	Goldman: Neutral	Oct-22-18
Initiated	Piper Jaffray: Overweight	Oct-22-18